These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28396735)

  • 1. Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase.
    Sanchez-Niño MD; Sanz AB; Ramos AM; Fernandez-Fernandez B; Ortiz A
    Clin Kidney J; 2017 Apr; 10(2):188-191. PubMed ID: 28396735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.
    Pontillo C; Mischak H
    Clin Kidney J; 2017 Apr; 10(2):192-201. PubMed ID: 28694965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.
    Rodríguez-Ortiz ME; Pontillo C; Rodríguez M; Zürbig P; Mischak H; Ortiz A
    Sci Rep; 2018 Oct; 8(1):15940. PubMed ID: 30374033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long path towards implementation of clinical proteomics: Exemplified based on CKD273.
    Nkuipou-Kenfack E; Zürbig P; Mischak H
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
    Critselis E; Lambers Heerspink H
    Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PeptiCKDdb-peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease.
    Krochmal M; Fernandes M; Filip S; Pontillo C; Husi H; Zoidakis J; Mischak H; Vlahou A; Jankowski J
    Database (Oxford); 2016; 2016():. PubMed ID: 27589965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.
    Filip S; Pontillo C; Peter Schanstra J; Vlahou A; Mischak H; Klein J
    Expert Rev Proteomics; 2014 Oct; 11(5):535-48. PubMed ID: 24957818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Origins, Technological Development, and Applications of Peptidomics.
    Schrader M
    Methods Mol Biol; 2018; 1719():3-39. PubMed ID: 29476501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics and personalized medicine: a focus on kidney disease.
    Siwy J; Mischak H; Zürbig P
    Expert Rev Proteomics; 2019 Sep; 16(9):773-782. PubMed ID: 31441341
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary proteomics in the assessment of chronic kidney disease.
    Mullen W; Delles C; Mischak H;
    Curr Opin Nephrol Hypertens; 2011 Nov; 20(6):654-61. PubMed ID: 21885967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary Peptidomic Biomarkers in Kidney Diseases.
    Sirolli V; Pieroni L; Di Liberato L; Urbani A; Bonomini M
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures!
    Mischak H
    Nephrol Dial Transplant; 2015 Apr; 30(4):532-7. PubMed ID: 25801638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
    Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
    Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a integrative multi-omics expression database CKDdb in the context of chronic kidney disease (CKD).
    Fernandes M; Husi H
    Sci Rep; 2017 Jan; 7():40367. PubMed ID: 28079125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaching clinical proteomics: current state and future fields of application in cellular proteomics.
    Apweiler R; Aslanidis C; Deufel T; Gerstner A; Hansen J; Hochstrasser D; Kellner R; Kubicek M; Lottspeich F; Maser E; Mewes HW; Meyer HE; Müllner S; Mutter W; Neumaier M; Nollau P; Nothwang HG; Ponten F; Radbruch A; Reinert K; Rothe G; Stockinger H; Tárnok A; Taussig MJ; Thiel A; Thiery J; Ueffing M; Valet G; Vandekerckhove J; Wagener C; Wagner O; Schmitz G
    Cytometry A; 2009 Oct; 75(10):816-32. PubMed ID: 19739086
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ortiz A
    Clin Kidney J; 2020 Oct; 13(5):723-727. PubMed ID: 33123351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease.
    Cisek K; Krochmal M; Klein J; Mischak H
    Nephrol Dial Transplant; 2016 Dec; 31(12):2003-2011. PubMed ID: 26487673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary peptidomics in kidney disease and drug research.
    Krochmal M; Schanstra JP; Mischak H
    Expert Opin Drug Discov; 2018 Mar; 13(3):259-268. PubMed ID: 29240457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.
    Lindhardt M; Persson F; Currie G; Pontillo C; Beige J; Delles C; von der Leyen H; Mischak H; Navis G; Noutsou M; Ortiz A; Ruggenenti PL; Rychlik I; Spasovski G; Rossing P
    BMJ Open; 2016 Mar; 6(3):e010310. PubMed ID: 26936907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.